tradingkey.logo

Renovaro Inc

RENB
1.420USD
0.000
收盤 12/22, 16:00美東報價延遲15分鐘
251.90M總市值
虧損本益比TTM

Renovaro Inc

1.420
0.000

關於 Renovaro Inc 公司

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Renovaro Inc簡介

公司代碼RENB
公司名稱Renovaro Inc
上市日期Nov 18, 2014
CEOWeinstein (David)
員工數量- -
證券類型Ordinary Share
年結日Nov 18
公司地址2080 Century Park East, Suite 906
城市LOS ANGELES
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編90067
電話14539179840
網址
公司代碼RENB
上市日期Nov 18, 2014
CEOWeinstein (David)

Renovaro Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
BMO Nesbitt Burns Inc.
5.79%
Gumrukcu (Serhat)
5.35%
其他
57.91%
持股股東
持股股東
佔比
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
BMO Nesbitt Burns Inc.
5.79%
Gumrukcu (Serhat)
5.35%
其他
57.91%
股東類型
持股股東
佔比
Corporation
31.30%
Investment Advisor
8.84%
Individual Investor
8.20%
Hedge Fund
1.12%
Investment Advisor/Hedge Fund
0.79%
Research Firm
0.03%
其他
49.72%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
144
2.83M
12.20%
+559.32K
2025Q2
156
65.41M
35.65%
+4.54M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
2023Q2
147
41.48M
71.99%
+3.87M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
RS Group ApS
1.68M
7.26%
+322.24K
+23.69%
Jul 15, 2025
Lakysa Ventures, Inc
2.15M
9.27%
+2.15M
--
Jul 15, 2025
PasecoApS
2.70M
11.65%
+1.44M
+113.93%
Jul 15, 2025
BMO Nesbitt Burns Inc.
1.36M
5.86%
+1.36M
--
Jul 15, 2025
Gumrukcu (Serhat)
1.25M
5.4%
--
--
Jul 15, 2025
The Vanguard Group, Inc.
492.46K
2.12%
-73.57K
-13.00%
Jun 30, 2025
William (Anderson Wittekind)
476.63K
2.06%
--
--
Jul 15, 2025
Millennium Management LLC
214.96K
0.93%
+213.51K
+14684.25%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
256.55K
1.11%
-424.73K
-62.34%
Jun 30, 2025
Geode Capital Management, L.L.C.
101.59K
0.44%
-135.17K
-57.09%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Sep 24, 2025
Merger
10→1
公告日期
類型
比率
Sep 24, 2025
Merger
10→1

常見問題

Renovaro Inc的前五大股東是誰?

Renovaro Inc的前五大股東如下:
RS Group ApS
持有股份:1.68M
佔總股份比例:7.26%。
Lakysa Ventures, Inc
持有股份:2.15M
佔總股份比例:9.27%。
PasecoApS
持有股份:2.70M
佔總股份比例:11.65%。
BMO Nesbitt Burns Inc.
持有股份:1.36M
佔總股份比例:5.86%。
Gumrukcu (Serhat)
持有股份:1.25M
佔總股份比例:5.40%。

Renovaro Inc的前三大股東類型是什麼?

Renovaro Inc 的前三大股東類型分別是:
RS Group ApS
Lakysa Ventures, Inc
PasecoApS

有多少機構持有Renovaro Inc(RENB)的股份?

截至2025Q3,共有144家機構持有Renovaro Inc的股份,合計持有的股份價值約為2.83M,占公司總股份的12.20% 。與2025Q2相比,機構持股有所增加,增幅為-23.45%。

哪個業務部門對Renovaro Inc的收入貢獻最大?

在--,--業務部門對Renovaro Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI